Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings
Bicara did better than experts thought in the second quarter, so analysts got more hopeful about the company's future. The stock went down anyway, which shows that good news doesn't always make a price go up right away.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.